These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30809716)

  • 21. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
    Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
    Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
    Miya A; Nakamura A; Cho KY; Kawata S; Nomoto H; Nagai S; Sugawara H; Taneda S; Tsuchida K; Omori K; Yokoyama H; Takeuchi J; Aoki S; Kurihara Y; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Aug; 12(8):1395-1399. PubMed ID: 33325645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular outcomes with canagliflozin - is it on the CANVAS?
    Doggrell SA
    Expert Opin Pharmacother; 2018 Feb; 19(2):163-166. PubMed ID: 29251018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors.
    Weeda ER; Cassarly C; Brinton DL; Shirley DW; Simpson KN
    J Diabetes Complications; 2019 Aug; 33(8):567-571. PubMed ID: 31176543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Clin Drug Investig; 2019 Feb; 39(2):179-186. PubMed ID: 30506378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
    Lee HF; Chen SW; Liu JR; Li PR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; See LC
    Cardiovasc Diabetol; 2020 Sep; 19(1):160. PubMed ID: 32998736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
    Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
    Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?
    Tanaka A; Node K
    Cardiovasc Diabetol; 2017 Oct; 16(1):129. PubMed ID: 29025400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
    Ueda P; Svanström H; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
    BMJ; 2018 Nov; 363():k4365. PubMed ID: 30429124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis.
    Potier L; Mohammedi K; Velho G; Roussel R
    Cardiovasc Diabetol; 2021 May; 20(1):107. PubMed ID: 33985506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?
    Misher A; Ampuero A; Phan R; Aziz S; Ebong E; Braich J; Dyches K; Southwood R
    Am J Ther; 2020 Mar; 28(1):e96-e110. PubMed ID: 32384319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension.
    Kimura T; Sanada J; Shimoda M; Hirukawa H; Fushimi Y; Nishioka M; Kinoshita T; Okauchi S; Obata A; Kohara K; Tatsumi F; Kamei S; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Investig; 2018 Jul; 9(4):875-881. PubMed ID: 29110406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Canagliflozin and Amputation Risk: Evidence So Far.
    Papadokostaki E; Rizos E; Tigas S; Liberopoulos EN
    Int J Low Extrem Wounds; 2020 Mar; 19(1):21-26. PubMed ID: 31698973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabetes.
    Camoin M; Velho G; Saulnier PJ; Potier L; Abouleka Y; Carpentier C; Dubois S; Larroumet A; Rigalleau V; Gand E; Bourron O; Bordier L; Scheen A; Hadjadj S; Roussel R; Marre M; Mohammedi K
    Cardiovasc Diabetol; 2022 May; 21(1):71. PubMed ID: 35534880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.
    Bajaj HS; Brown RE; Bhullar L; Sohi N; Kalra S; Aronson R
    Diabetes Metab; 2018 Dec; 44(6):493-499. PubMed ID: 30149145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
    Oshima M; Neuen BL; Jardine MJ; Bakris G; Edwards R; Levin A; Mahaffey KW; Neal B; Pollock C; Rosenthal N; Wada T; Wheeler DC; Perkovic V; Heerspink HJL
    Lancet Diabetes Endocrinol; 2020 Nov; 8(11):903-914. PubMed ID: 33065060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.